Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Anti-IgE antibody therapy.

Donald MacGlashan1

  • 1Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Clinical Allergy and Immunology
|October 2, 2001
PubMed
Summary

The drug E25 shows promise in treating atopic diseases by effectively reducing immunoglobulin E (IgE) levels. Further research is needed to address long-term effects, parasitic disease roles, and cost for widespread patient benefit.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy of the 4 Subclasses of IgG for Interacting With CD32b/a on Human Basophils.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2025
Same author

Association of a SYK promoter polymorphism with SYK expression and IgE-mediated histamine release.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2023
Same author

Biological screening of a unique drug library targeting MRGPRX2.

Frontiers in immunology·2022
Same author

Subclasses of allergen-specific IgG: Serum IgG2 and IgG3 levels are not predicted by IgG1/IgG4 levels.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2021
Same author

Response of peripheral blood basophils in subjects with chronic spontaneous urticaria during treatment with omalizumab.

The Journal of allergy and clinical immunology·2021
Same author

The relationship between released soluble FceRI-alpha and its cell surface density on human basophils.

PloS one·2021

Area of Science:

  • Immunology
  • Allergy and Dermatology
  • Pharmacology

Background:

  • Atopic diseases, including asthma, are complex conditions with ongoing debates about the role of immunoglobulin E (IgE).
  • Existing treatments aim to manage symptoms, but a definitive approach to reducing IgE levels has been sought.
  • Understanding the precise contribution of atopy to disease pathogenesis is crucial.

Purpose of the Study:

  • To evaluate the efficacy of E25 in treating atopic diseases by targeting IgE.
  • To provide a tool for investigating the role of IgE in various diseases, particularly asthma.
  • To assess E25 as a proof-of-concept for therapies aimed at reducing circulating IgE.

Main Methods:

  • Published studies on E25 were reviewed.
  • The drug's ability to eliminate IgE was assessed.
  • Dosing regimens were considered for optimal outcomes.

Main Results:

  • E25 demonstrates success in treating atopic disease by effectively eliminating IgE with appropriate dosing.
  • The drug offers a novel tool for researchers to explore IgE's role in disease expression.
  • It provides a proof-of-concept for IgE-lowering therapies.

Conclusions:

  • E25 presents a potentially remarkable improvement for atopic diseases, contingent on proper dosing.
  • Further investigation is required regarding IgE's role in parasitic diseases, therapy costs, and long-term treatment effects.
  • The drug facilitates critical research into the function of IgE in health and disease.

Related Experiment Videos